VanEck Biotech ETF (NQ:BBH)

240.47 +6.43 (+2.75%)

Official Closing Price Updated: 4:15 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about VanEck Biotech ETF

< Previous 1 2 Next >

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

Via The Motley Fool

Topics ETFs

VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗

September 15, 2026

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗

August 28, 2026

VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

Via The Motley Fool

Topics ETFs

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗

February 10, 2026

Via Stocktwits

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗

August 22, 2026

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

Via The Motley Fool

Topics ETFs

In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? ↗

August 20, 2026

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Via The Motley Fool

Topics ETFs

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗

August 05, 2026

XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.

Via The Motley Fool

Topics ETFs

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗

July 28, 2026

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

Via The Motley Fool

Topics ETFs

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗

July 23, 2026

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

Via The Motley Fool

Topics ETFs

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗

July 14, 2026

RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗

July 08, 2026

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

Via The Motley Fool

Topics ETFs

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗

July 04, 2026

Compare fees, diversification, and risk between these two leading healthcare ETFs.

Via The Motley Fool

Topics ETFs

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

Via Talk Markets

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...

Via Benzinga

VanEck Announces Year-End Distributions for VanEck Equity ETFs

December 19, 2025

From VanEck

Via Business Wire

VanEck Announces Year-End Distributions for VanEck Equity ETFs

December 20, 2024

From VanEck

Via Business Wire

VanEck Announces Year-End Distributions for VanEck Equity ETFs

December 15, 2023

From VanEck

Via Business Wire

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

VanEck Launches Robotics ETF (IBOT)

April 06, 2023

From VanEck

Via Business Wire

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

3 Best Funds for Aggressive Investors ↗

August 11, 2022

These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year.

Via InvestorPlace

Progenity Is Unlikely to Live Up to Its IPO Hype ↗

December 15, 2021

Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?

Via InvestorPlace

Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money ↗

June 22, 2022

With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in.

Via InvestorPlace

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.